Protagonist Therapeutics, Inc.
PTGX
Rank in Stocks
#2295
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Share Price
$134.37
Last synced: 2026-10-19
Market Cap
$8.70B
Change (1 day)
4.37%
Change (1 year)
75.15%
Country
US
Trade Protagonist Therapeutics, Inc. (PTGX)
Category
Healthcare
Earnings for Protagonist Therapeutics, Inc. (PTGX)
Earnings in Jun 2026 TTM: $84.34M
According to Protagonist Therapeutics, Inc. latest financial reports the company's current earnings are $84.34M. In 2023 the company made an earning of $-78.96M, an increase over its 2022 earnings that were of $-127.39M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Protagonist Therapeutics, Inc. from 2014 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $84.34M | -69.82% |
| 2024 | $279.41M | -453.88% |
| 2023 | $-78.96M | -38.02% |
| 2022 | $-127.39M | 1.47% |
| 2021 | $-125.55M | 93.62% |
| 2020 | $-64.85M | -16.74% |
| 2019 | $-77.88M | 96.05% |
| 2018 | $-39.72M | 7.48% |
| 2017 | $-36.96M | -0.59% |
| 2016 | $-37.18M | 150.22% |
| 2015 | $-14.86M | 34.19% |
| 2014 | $-11.07M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | 6,154.48% |
US
|
|
| $-3.09B | -3,760.27% |
US
|
|
| $-4.02B | -4,862.02% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 2,212.90% |
NL
|
